SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-037646
Filing Date
2022-11-14
Accepted
2022-11-14 16:36:17
Documents
63
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20220930.htm   iXBRL 10-Q 2356911
2 EX-31.1 achv-ex311_6.htm EX-31.1 9069
3 EX-32.1 achv-ex321_7.htm EX-32.1 4892
4 GRAPHIC ggextnpigrgb000001.jpg GRAPHIC 92401
  Complete submission text file 0001564590-22-037646.txt   7849795

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA achv-20220930.xsd EX-101.SCH 53147
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20220930_cal.xml EX-101.CAL 38534
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20220930_def.xml EX-101.DEF 199492
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20220930_lab.xml EX-101.LAB 391359
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20220930_pre.xml EX-101.PRE 299760
57 EXTRACTED XBRL INSTANCE DOCUMENT achv-10q_20220930_htm.xml XML 1299748
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 221386598
SIC: 2835 In Vitro & In Vivo Diagnostic Substances